Kane Biotech Inc. V.KNE

Alternate Symbol(s): KNBIF

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.

TSXV:KNE - Post by User

Kane Biotech Inc. > News Release: Further information…

<< Previous

Bullboard Posts

Next >>

Comment by RoyMax123on Jan 27, 2023 1:04pm

97 Views

Post# 35250468

RE:RE:RE:News Release: Further information…

BTW,

He also posted that vids, listen at around 2Min
https://www.paidpromotionalmessages.com/companies/news/1004091/kane-biotech-announces-distribution-agreement-for-coactiv-antimicrobial-hydrogel-1004091.htm

RoyMax123 wrote: someone posted this on CEO
https://ceo.ca/kne?af99af499987

So I think we'll have to wait a bit more.

francoisl13 wrote: The FDA site is updated every Monday (see lik below);
CRDH 510k Approval database
Based on KNE submitting their file in October and info provided by MirroWorldMan, I expect the coactiv+ approval to be published on Monday January 30th (earliest) or February 6th.
GLTA